Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients

Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27.

Authors

Hélène Monjanel¹, Laure Deville, Caroline Ram-Wolff, Marie-Dominique Venon, Patricia Franchi, Claire Benet, Eric de Kerviler, Marion Malphettes, Catherine Thieblemont, Pauline Brice

Affiliation

¹ Department of Hemato-oncology, Hôpital Saint-Louis, AP-HP, Paris, France.

PMID: 24673542
DOI: 10.1111/bjh.12849

No abstract available

Keywords: Hodgkin lymphoma; anaplastic large-cell lymphoma; brentuximab vedotin; monoclonal antibody; primary refractory.

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Hodgkin Disease / drug therapy*
Humans
Immunoconjugates / therapeutic use*
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Middle Aged
Recurrence
Retrospective Studies
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Immunoconjugates
Brentuximab Vedotin